Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the leading cause of treatment failure in high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), yet effective maintenance strategies are currently lacking. The combination of chidamide (CHI) and venetoclax (VEN) re...